Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.

You may also be interested in...



Amgen's Blincyto Is First Cancer Drug To Get Medicare Add-On Payments

CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.

Antibiotic Disincentives? Medicare Decisions Underscore Limits Of Add-On Payments

CMS disappointed stakeholders looking for antibiotic payment incentives from Medicare with two recent decisions. One was to withhold new technology add-on payments from Dalvance and the other to allow existing NTAP benefits for Dificid to expire.

The Medicines Co. Joins Crowded Antibiotic Field With Q4 Orbactiv Launch

Company is banking on its single-dose treatment course to propel it over competitors in a crowded generic and branded space, but this may involve major changes in treatment practice, analysts say.

Related Content

Topics

UsernamePublicRestriction

Register

PS074533

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel